

0590
#6
pif
18-88-07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Group Art Unit: To Be Assigned

SMITH et al.

Examiner: To Be Assigned

Appln. No.: 09/773,599

Filed: February 2, 2001

FOR: DIAGNOSTIC METHOD

Date: June 14, 2001

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Attached is a Form PTO-1449 listing the enclosed documents.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee is under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 009901/0276655 and proceed to consider this IDS.


This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Respectfully Submitted,

PILLSBURY WINTHROP LLP

By:



Pillsbury Winthrop LLP
1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005-3918
DJB:amx

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 861-3027
Fax No.: (202) 822-0944

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.


M#

Client Ref.

0276655

PHM 70655/US

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**



Date: June 14, 2001

1

of

2

Applicant: SMITH et al.

Appln. No.: 09/773,599

Filing Date: February 2, 2001

Examiner: To Be Assign

Group Art Unit: To Be Assign

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
				Enclosed	No
ER					
FR					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

GR	EMBL Accession No. AC006953 Homo sapiens chromosome 19, cosmid R28316, complete sequence 38727 bp
HR	J Aceto, T Kieber-Emmons and DB Cines (1999) Carboxy-terminal processing of the urokinase receptor: implications for substrate recognition and glucosylphosphatidylinositol anchor addition. Biochemistry 38, pg. 992-1001
IR	JR Casey, JG Petranka, J Kottra, DE Fleenor and WF Rosse (1994) The structure of the urokinase-type plasminogen activator receptor gene. Blood 84, pg. 1151-1156
JR	LJ Curtis, Y Li, M Gerbault-Seureau, R Kuick, A-M Dutrillaux, G Goubin, J Fawcett, S Cram, B Dutrillaux, S Hanash and M Muleris (1998) Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines. Genomics 53, pg. 42-55
KR	J Dang, D Boyd, H Wang, H Allgayer, WF Doe and Y Wang (1999) A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem 264, pg. 92-99
LR	MRJ Kohonen-Corish, Y Wang and WF Doe (1996) A highly polymorphic CA/GT repeat in intron 3 of the human urokinase receptor gene (PLAUR). Human Genetics 97, pg. 124-125
MR	LB Moller, M Ploug and F Blasi (1992) Structural requirements for glycosyl-phosphatidyl-anchor attachment in the cellular receptor for urokinase plasminogen activator. Eur J Biochem 208, pg. 493-500
NR	M Ploug and V Ellis (1994) Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Letters 349, pg. 163-168

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

0276655

PHM 70655/US

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: SMITH et al.

Appln. No.: 09/773,599

Filing Date: February 2, 2001

Examiner: To Be Assign

Group Art Unit To Be Assign

Date: June 14, 2001

Page

2

of

2

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	HR							
	IR							
	JR							
	KR							
	LR							
	MR							
	NR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	OR	C Pyke, J Eriksen, H Solberg, B Schnack Nielsen, P Kristensen, LR Lund and K Dano (1993) An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Letters 326, pg. 69-74
	PR	E Soravia, A Grebe, P De Luca, K Helin TT Suth, JL Degen, and F Blasi (1995) A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood 86, pg. 624-635
	QR	Y Wang, J Dang, LK Johnson, JJ Selhamer and WF Doe (1995) Structure of the urokinase receptor gene and its similarity to CD59 and the Ly-6 family. Eur J Biochem 227, pg. 116-122
	RR	G Webb, MS Baker, J Nicholl, Y Wang, G Woodrow, E Kruithof and WF Doe (1994) Chromosomal Localisation of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer. J Gastroenterol Hepatol 9, pg. 340-343
	SR	
	TR	
	UR	

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.